IL-17A Influences Essential Functions of the Monocyte/Macrophage Lineage and Is Involved in Advanced Murine and Human Atherosclerosis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Atherosclerosis is a chronic inflammatory disease. Lesion progression is primarily mediated by cells of the monocyte/macrophage lineage. IL-17A is a proinflammatory cytokine, which modulates immune cell trafficking and is involved inflammation in (auto)immune and infectious diseases. But the role of IL-17A still remains controversial. In the current study, we investigated effects of IL-17A on advanced murine and human atherosclerosis, the common disease phenotype in clinical care. The 26-wk-old apolipoprotein E–deficient mice were fed a standard chow diet and treated either with IL-17A mAb (n = 15) or irrelevant Ig (n = 10) for 16 wk. Furthermore, essential mechanisms of IL-17A in atherogenesis were studied in vitro. Inhibition of IL-17A markedly prevented atherosclerotic lesion progression (p = 0.001) by reducing inflammatory burden and cellular infiltration (p = 0.01) and improved lesion stability (p = 0.01). In vitro experiments showed that IL-17A plays a role in chemoattractance, monocyte adhesion, and sensitization of APCs toward pathogen-derived TLR4 ligands. Also, IL-17A induced a unique transcriptome pattern in monocyte-derived macrophages distinct from known macrophage types. Stimulation of human carotid plaque tissue ex vivo with IL-17A induced a proinflammatory milieu and upregulation of molecules expressed by the IL-17A–induced macrophage subtype. In this study, we show that functional blockade of IL-17A prevents atherosclerotic lesion progression and induces plaque stabilization in advanced lesions in apolipoprotein E–deficient mice. The underlying mechanisms involve reduced inflammation and distinct effects of IL-17A on monocyte/macrophage lineage. In addition, translational experiments underline the relevance for the human system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Macrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669
Kadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R., Kastelein, R. A., Bazan, F., & Liu, Y.-J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.863 · Cited by 1,964 · cited 6×
“For T cell activation assays, macrophages or DCs were incubated in 96- well round-bottom plates in RPMI 1640 supplemented with 10% FCS and stimulated with 20 mg/ml oxidized LDL (oxLDL; Sanbio), 100 ng/ml IL17A (R&D Systems), or oxLDL in combination with IL-17A for 6 h.”
BackgroundInfluentialIL-17 family cytokines and the expanding diversity of effector T cell lineages
Weaver, C. T., Hatton, R. D., Mangan, P. R., & Harrington, L. E. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141557 · Cited by 1,842 · cited 6×
“We already showed that IL-17A inhibition reduces lesional chemokine ex- pression (CCL5) in early atherosclerotic lesions and IL-17A induces expression of adhesion molecules on endothelial cells (VCAM-1) (5, 7).”
BackgroundInfluentialLocal proliferation dominates lesional macrophage accumulation in atherosclerosis
Robbins, C. S., Hilgendorf, I., Weber, G. F., Theurl, I., Iwamoto, Y., Figueiredo, J.-L., Gorbatov, R., Sukhova, G. K., Gerhardt, L. M. S., Smyth, D., et al. (2013) · Nature Medicine · doi:10.1038/nm.3258 · Cited by 1,041 · cited 1×
“Recent studies have shown that plaque progression is predominantly caused by monocyte recruitment and/or local proliferation of macrophages (2, 3), whereas plaque stabi-”
BackgroundMichelsen, K. S., Wong, M. H., Shah, P. K., Zhang, W., Yano, J., Doherty, T. M., Akira, S., Rajavashisth, T. B., & Arditi, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403249101 · Cited by 1,019 · cited 1×
“mice showed reduced atherosclerotic lesions (42).”
Gautier, E. L., Jakubzick, C., & Randolph, G. J. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.180505 · Cited by 216
CXCL4 Downregulates the Atheroprotective Hemoglobin Receptor CD163 in Human Macrophages
Gleissner, C. A., Shaked, I., Erbel, C., Böckler, D., Katus, H. A., & Ley, K. (2010) · Circulation Research · doi:10.1161/circresaha.109.199505 · Cited by 165 · cited 1×
“Gene chip data were analyzed as described previously (16).”
MethodSelf-citation
Cited by
Macrophage Phenotype and Function in Different Stages of Atherosclerosis
Tabas, I., & Bornfeldt, K. E. (2016) · Circulation Research · doi:10.1161/circresaha.115.306256 · Cited by 1,121
“phages were suggested to constitute a new macrophage population distinct from M1, M2, and M4 macrophages.(21)”
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Blauvelt, A., & Chiricozzi, A. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-018-8702-3 · Cited by 789
Management of psoriasis as a systemic disease: what is the evidence?
Korman, N. J. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18245 · Cited by 539
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets
Ramji, D. P., & Davies, T. S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.04.003 · Cited by 469
Interleukin-17 and innate immunity in infections and chronic inflammation
Isailovic, N., Daigo, K., Mantovani, A., & Selmi, C. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.04.006 · Cited by 363
The Immunology of Psoriasis-Current Concepts in Pathogenesis
Sieminska, I., Pieniawska, M., & Grzywa, T. M. (2024) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-024-08991-7 · Cited by 346
“Moreover, IL-17 activates the pro-inflammatory phenotype of monocytes/macrophages and sensitizes them toward pathogen-derived TLR4 ligands [162].”
BackgroundSystemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences
Boehncke, W.-H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00579 · Cited by 307
Chronic graft-versus-host disease: biological insights from preclinical and clinical studies
MacDonald, K. P. A., Hill, G. R., & Blazar, B. R. (2017) · Blood · doi:10.1182/blood-2016-06-686618 · Cited by 300
Nalkurthi, C., Schroder, W. A., Melino, M., Irvine, K. M., Nyuydzefe, M., Chen, W., Liu, J., Teng, M. W. L., Hill, G. R., Bertolino, P., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2021.100386 · Cited by 75
Childhood Obesity: Immune Response and Nutritional Approaches
Magrone, T., & Jirillo, E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00076 · Cited by 67
Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis
Varshney, P., Narasimhan, A., Mittal, S., Malik, G., Sardana, K., & Saini, N. (2016) · Scientific Reports · doi:10.1038/srep19295 · Cited by 64
Characterization of Lamprey IL-17 Family Members and Their Receptors
Han, Q., Das, S., Hirano, M., Holland, S. J., McCurley, N., Guo, P., Rosenberg, C. S., Boehm, T., & Cooper, M. D. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500892 · Cited by 60
Metadata
- Authors
- Erbel, C., Akhavanpoor, M., Okuyucu, D., Wangler, S., Dietz, A., Zhao, L., Stellos, K., Little, K. M., Lasitschka, F., Doesch, A., Hakimi, M., Dengler, T. J., Giese, T., Blessing, E., Katus, H. A., & Gleissner, C. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-11-01
- Volume
- 193
- Issue
- 9
- Pages
- 4344-4355
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2102370935
- Cited by
- 151
- References
- 8
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.